Pyxis Oncology, Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses), averaging -2.1% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.34 | $-0.40 | -17.6% | Miss | |
| Q1 FY26 | $-0.35 | $-0.37 | -5.7% | Miss | |
| Q4 FY25 | $-0.35 | $-0.29 | +17.1% | Beat |
Back to PYXS overview · PYXS holders · PYXS KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.